Verena and Anja delve into the lessons learned from the first 18 months of the Unified Patent Court (UPC). They provide an overview of how the UPC is shaping patent litigation in the pharma and biotech sectors, particularly in relation to preliminary injunctions. They explain key considerations for patentees seeking to enforce their rights and for potential defendants aiming to navigate the complexities of the new system.

Through their analysis, they highlight important procedural and substantive differences between the UPC and national courts, offering guidance on the legal strategies that may be most effective in these cases. As the UPC becomes an increasingly significant forum for patent disputes, Verena and Anja offer valuable insights into the evolving landscape, helping both patentees and defendants better understand the risks and opportunities presented by the court's approach to patent injunctions.

Register now